Novo Nordisk has announced that it will maintain the availability of its popular insulin brand, Mixtard, in vial form in India, despite discontinuing Penfill cartridges. The decision comes amid worries about the removal of widely utilized insulin products. The company’s objective is to streamline its insulin offerings to address the rising need from patients and guarantee a consistent medication supply by emphasizing newer therapies.